Key terms
About EW
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EW news
Yesterday
8:08am ET
Edwards Lifesciences price target raised to $101 from $95 at RBC Capital
Apr 11
7:00am ET
Edwards Lifesciences price target raised to $105 from $95 at Mizuho
Apr 08
8:19am ET
SMART data a ‘modest win’ for Medtronic, says Jefferies
Apr 05
12:16am ET
Evercore ISI Remains a Hold on Edwards Lifesciences (EW)
Apr 03
5:51am ET
Edwards Lifesciences price target raised to $98 from $90 at Citi
Mar 26
4:24pm ET
Edwards Lifesciences Announces Upcoming Board Chair Transition
Mar 21
8:01am ET
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Edwards Lifesciences (EW) and Innovent Biologics (OtherIVBXF)
Mar 21
7:56am ET
Edwards Lifesciences price target raised to $103 from $95 at Morgan Stanley
Mar 18
7:50am ET
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)
Mar 18
7:40am ET
Edwards Lifesciences price target raised to $100 from $93 at Oppenheimer
Mar 14
6:40am ET
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR)
Mar 13
4:15am ET
Buy Rating on Edwards Lifesciences Amid Expanding TAVR Market and Positive SMART Trial Outlook
Mar 07
9:53am ET
Micron upgraded, Foot Locker downgraded: Wall Street’s top analyst calls
Mar 07
9:07am ET
Edwards Lifesciences upgraded to Buy at BofA after ‘bullish’ management meetings
Mar 07
6:03am ET
Edwards Lifesciences upgraded to Buy from Neutral at BofA
Feb 26
6:32am ET
Edwards Lifesciences (EW) Gets a Buy from Wells Fargo
Feb 12
5:47am ET
Wells Fargo Reaffirms Their Buy Rating on Edwards Lifesciences (EW)
Feb 08
6:57am ET
Edwards Lifesciences price target raised to $100 from $90 at Barclays
Feb 08
6:27am ET
Barclays Remains a Buy on Edwards Lifesciences (EW)
Feb 07
1:15pm ET
Buy Rating Affirmed for Edwards Lifesciences on Evoque TTVR System’s FDA Approval and Promising Trial Results
Feb 07
9:03am ET
Edwards Lifesciences price target raised to $86 from $64 at Deutsche Bank
Feb 07
9:01am ET
Edwards Lifesciences price target raised to $95 from $82 at RBC Capital
Feb 07
8:41am ET
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Qiagen (QGEN) and Inspire Medical Systems (INSP)
Feb 07
8:38am ET
Edwards Lifesciences price target raised to $86 from $81 at Canaccord
Feb 07
8:28am ET
Maintaining Hold on Edwards Lifesciences Amid Balanced Growth and Adequate Valuation
Feb 07
8:12am ET
Edwards Lifesciences price target raised to $97 from $84 at Truist
Feb 07
7:56am ET
Edwards Lifesciences (EW) Receives a Buy from Oppenheimer
Feb 07
7:31am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Edwards Lifesciences (EW) and Omnicell (OMCL)
Feb 07
7:25am ET
Edwards Lifesciences price target raised to $100 from $90 at TD Cowen
Feb 07
7:01am ET
Edwards Lifesciences price target raised to $92 from $84 at UBS
Feb 07
6:53am ET
Edwards Lifesciences price target raised to $100 from $85 at Baird
No recent press releases are available for EW
EW Financials
Key terms
Ad Feedback
EW Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EW Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
